<DOC>
	<DOCNO>NCT00015977</DOCNO>
	<brief_summary>RATIONALE : Vaccines make patient 's white blood cell may make body build immune response kill cancer cell . Interleukin-12 may kill cancer cell stop blood flow tumor stimulate person 's white blood cell kill cancer cell . Combining vaccine therapy interleukin-12 may kill tumor cell . PURPOSE : Phase II trial study effectiveness vaccine therapy combine interleukin-12 treating patient metastatic prostate cancer respond hormone therapy .</brief_summary>
	<brief_title>Vaccine Therapy Plus Interleukin-12 Treating Patients With Metastatic Prostate Cancer That Has Not Responded Hormone Therapy</brief_title>
	<detailed_description>OBJECTIVES : - Determine whether immunization prostate-specific membrane antigen-pulsed autologous peripheral blood mononuclear cell interleukin-12 promote specific T-cell priming patient metastatic hormone-refractory prostate cancer . - Determine clinical response patient treat regimen . OUTLINE : Patients receive prostate-specific membrane antigen-pulsed autologous peripheral blood mononuclear cell subcutaneously ( SC ) day 1 interleukin-12 SC day 1 , 3 , 5 . Treatment repeat every 21 day 3-9 course absence disease progression unacceptable toxicity . Patients follow every 3 month . PROJECTED ACCRUAL : A total 12-37 patient accrue study within 37 week .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Interleukin-12</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm metastatic adenocarcinoma prostate HLAA2 positive Progressive measurable systemic disease PSA least 5 ng/mL 2 consecutive rise PSA level least 1 week apart measurable disease OR Objective evidence disease progression 20 % increase sum long diameter target lesion evidence new lesion CT bone scan regardless PSA status Lesions must least 1 cm consider measurable Progressive systemic disease discontinuation antiandrogen therapy Previously treat orchiectomy ( testosterone less 50 ng/mL ) OR luteinizing hormonereleasing hormone ( LHRH ) analogue therapy without antiandrogens If LHRH analogue therapy , must continue therapy study Brain metastasis allow previously treat , clinically stable , wean prior corticosteroid PATIENT CHARACTERISTICS : Age : Over 18 Performance status : Karnofsky 70100 % Life expectancy : At least 12 week Hematopoietic : Absolute neutrophil count great 1,500/mm^3 Hemoglobin great 9 g/dL Platelet count great 100,000/mm^3 No active gastrointestinal bleeding Hepatic : Bilirubin le 1.5 time upper limit normal ( ULN ) SGPT normal Hepatitis B surface antigen negative Renal : Creatinine le 1.5 time ULN Calcium le 11 mg/dL Cardiovascular : No significant cardiovascular disease No cardiac arrhythmia require therapy Other : Fertile patient must use effective barrier contraception No intrinsic immunosuppression HIV negative No serious concurrent infection No psychiatric illness would preclude study compliance No clinically significant autoimmune disease No uncontrolled peptic ulcer disease No history inflammatory bowel disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior biologic therapy Chemotherapy : Not specify Endocrine therapy : See Disease Characteristics At least 4 week since prior flutamide At least 6 week since prior bicalutamide nilutamide No concurrent systemic corticosteroid except physiologic replacement dos Radiotherapy : Not specify Surgery : See Disease Characteristics Other : No concurrent immunosuppressive drug ( e.g. , cyclosporine )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>adenocarcinoma prostate</keyword>
	<keyword>stage IV prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>